Pain Management

Chronic Pain Management

Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial

Noppers I, Niesters M, Swartjes M, et al (Leiden Univ Med Ctr, The Netherlands) Eur J Pain 15:942-949, 2011^§

Abstract

To assess the analgesic efficacy of the N-methyl-d-aspartate receptor antagonist S(+)-ketamine on fibromyalgia pain, the authors performed a randomized double blind, active placebo-controlled trial. Twenty-four fibromyalgia patients were randomized to receive a 30-min intravenous infusion with S(+)-ketamine (total dose 0.5 mg/kg, n = 12) or the active placebo, midazolam (5 mg, n = 12). Visual Analogue Pain Scores (VAS) and ketamine plasma samples were obtained for 2.5-h following termination of treatment; pain scores derived from the fibromyalgia impact questionnaire (FIQ) were collected weekly during an 8-week follow-up. Fifteen min after termination of infusion the number of patients showing a reduction in pain scores >50% was 8 vs. 3 (P < 0.05), at t = 180 min 6 vs. 2 (ns), at the end of week-1 2 vs. 0 (ns) and at end of week-8 2 vs. 2 in the ketamine and midazolam groups, respectively. Ketamine effect on VAS closely followed ketamine plasma concentrations. For VAS and FIQ scores no significant differences in treatment effects were observed in the 2.5-h following infusion or during the 8-week follow-up. Side effects as measured by the Bowdle questionnaire (which scores for 13 separate psychedelic symptoms) were mild to moderate in both study groups and declined rapidly, indicating adequate blinding of treatments. Efficacy of ketamine was limited and restricted in duration to its pharmacokinetics. The authors argue that a short-term infusion of ketamine is insufficient to induce long-term analgesic effects in fibromyalgia patients (Figs 2–4).

Figure 2 (A) Mean plasma concentrations of S-ketamine and S-norketamine in patients that received a 30-min S-ketamine infusion (gray bar). (B) Effect of a 30-min treatment with S-ketamine (0.5 mg/kg, closed circles, n = 12) and midazolam (5 mg, open squares, n = 12) on pain scores in fibromyalgia patients. No significant differences in pain relief between the two treatment was observed during the treatment recovery phase (t = 45 to t = 180 min). The gray bar indicates the treatment period. Data are mean ± SEM. (Reprinted from Noppers I, Niesters M, Swartjes M, et al. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. Eur J Pain. 2011;15:942-949, Copyright 2011, with permission from European Federation of International Association for the Study of Pain Chapters.)

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

of change in daily step count over five years with insulin sensitivity and adiposity: population based cohort study of Cancer: The Next Generation Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes: A meta-analysis time and haemodynamic response after thiopental vs. propofol in the elderly: a randomized trial monitoring of neuromuscular block over the orbicularis oris muscle in anesthetized patients receiving vecuronium Is Better Than General Anesthesia During Endovascular Acute Stroke Interventions